US Clinical Trial Supplies Market Size Likely to Grow at a CAGR of 7.4% By 2035

The U.S. clinical trial supplies market is valued at approximately USD 1.25 billion in 2025, expected to reach nearly USD 1.34 billion in 2026, and projected to grow to around USD 2.53 billion by 2035, expanding at a CAGR of 7.4% from 2026 to 2035.

Clinical Trial Supplies Market Revenue and Trend of the U.S.

It is estimated that from 2026 to 2035, the U.S. clinical trial supplies market would experience a consistent growth in revenue as a result of the rise in the number of clinical trials in the pharmaceuticals, biotechnology, and academic research industries. The increase in the use of decentralized and hybrid trial models, growth of cold-chain logistics and increasing demand on biologics, gene therapies, and personalized medicines are among the driving forces of growth.

The supply chain is becoming efficient and safer for patients due to technological changes in packaging, labeling, controlled distribution by use of temperature, and real time tracking solutions. Favorable regulatory controls by the FDA, growth of the direct-to-patient (DTP) distribution channels and growing involvement of a contract research organization (CRO) are all contributing to long-term market growth.

Which are the Factors that make a Contribution?

The increasing clinical trials of complexity and multi-site, the need for accuracy in cold-chain supply, and the usage of patient-centric supply models are some of the major drivers in the U.S. market of clinical trial supplies. Sponsors and CROs are increasingly adopting technological advances that improve real-time monitoring, assembling kits and labelling them correctly, and ensuring they maintain a specific temperature to improve logistics. Increased interest in regulatory compliance, faster drug development cycles, and the rising use of outsourcing in immersing its supply to full-service and hybrid suppliers are also driving the growth of the market. Also, there is an increase in investments by the major service providers into the expansion of infrastructure, cold-chain, and regional depots that are contributing to increasing access to clinical trial materials, which will propel the market consistently throughout the forecast period.

By Supply Type

Investigational medicinal products are the largest category since they are essential in all stages of clinical trials such as novel biologics, small molecules and gene therapies. The use of comparator drugs is still experiencing a consistent demand for controlled studies and regulatory compliance in trials. Ancillary supplies, which include syringes, infusion sets, and monitoring devices, are increasing because of the increased trends in the decentralized and home-based trial models. Lab kits are becoming popular in the use of biomarkers, sample collection and remote patient monitoring. Packaging and labels are still required in order to comply with regulations, cold-chain preservation, and tracking. Other supplies such as storage containers, temperature sensors and patient support kits are constantly increasing with increasing volumes of trials.

By Trial Phase

The first-in-human studies in the Phase I trials need accurate and small-scale supply management including intensive cold-chain support and monitoring. Due to the rising phase II trials in which sponsors are investigating efficacy on a broader population of patients, the packaging, labeling, and distribution solutions are in demand. Phase III trials have a considerable amount of supply consumption because of the scale, multi-location distribution, and regulatory demands. The trials at phase IV have been on the increase because post-marketing trials involve continuous provision of investigative products, patient monitoring packs, and services.

By Service Model

Full-service providers are the most dominant as they provide end-to-end supply chain services such as packaging, labeling, storage, distribution, and tracking. The functional service providers are becoming an increasingly popular way of sponsoring because sponsors choose to outsource logistics or temperature monitoring or put together a kit selectively and on demand. Hybrid models use a mixture of full-service and functional options, which offer versatile solutions to the complex or multi-site trials along with optimal use of costs and efficiency.

By Therapeutic Area

The greatest demand in clinical trial supplies is for oncology trials because of rising cancer research and personalized medicine programs. Trial of cardiovascular drugs is a sensitive dosing and temperature-controlled storage together with a special monitoring kit. With more and better treatments being developed to treat Alzheimer, Parkinson and other neurological disorders, neurology trials are continuing to grow. Trials on infectious diseases are on the rise, particularly in regard to vaccines, antivirals and studies into new pathogens. Trials of rare diseases require extremely unique supply chain solutions due to the limited number of patients. The rest of the therapeutic product markets, such as immunology and endocrinology, all help in the general growth of the market.

By Distribution Strategy

Direct-to-site (DTS) is the most commonly used method of distributing investigational products to hospitals and clinical sites in order to deliver them on time. Direct-to-patient (DTP) is expanding at a high rate particularly in the case of decentralized and virtual trials where patients work with kits at home with correct cold-chain and monitoring maintenance. The central depot models are popular in the case of multi-site trials where the central coordination of storage, labeling, and distribution is needed. The depot models that are being embraced more often are regional depot models to minimize lead times, enhance temperature regulation and facilitate large-scale studies or studies that are geographically dispersed.

By End User

The greatest end users are pharmaceutical companies, which influence the supply and demand of all the trial phases and therapeutic areas. The trend towards growing biologics, cell, and gene therapy trials is causing the use of biotechnology by the companies to expand. CROs are also large intermediaries that provide the complicated logistics of trials such as assembling, packaging, and distributing kits. The academic research institutes will also help in demand where investigator-initiated studies and clinical research in special therapeutic fields are required.

Report Scope

Recent Developments

• UDG Healthcare increased its U.S. presence in March 2025 through additional support of its clinical trial packaging, labeling, and distribution services, which facilitate quicker supply chain management of biologics and investigational medicines.

List of the prominent players in the US Clinical Trial Supplies Market:

• Thermo Fisher Scientific

• Catalent

• PCI Pharma Services

• Marken

• Parexel International

• Piramal Pharma Solutions

• UDG Healthcare

• UPS Healthcare

• DHL

• FedEx

• Almac Group

• Biocair International

• Others

The US Clinical Trial Supplies Market is segmented as follows:

By Supply Type

• Investigational Medicinal Products

• Comparator Drugs

• Ancillary Supplies

• Lab Kits

• Packaging & Labeling Materials

• Others

By Trial Phase

• Phase I

• Phase II

• Phase III

• Phase IV

By Service Model

• Full-Service Providers

• Functional Service Providers

• Hybrid Models

By Therapeutic Area

• Oncology

• Cardiovascular

• Neurology

• Infectious Diseases

• Rare Diseases

• Others

By Distribution Strategy

• Direct-to-Site

• Direct-to-Patient

• Central Depot Model

• Regional Depot Model

By End User

• Pharmaceutical Companies

• Biotechnology Firms

• Contract Research Organizations

• Academic Research Institutes